Salome Charalambous

List of Publications by Year
in descending order

89 papers	3,230 citations	201674 27 h-index	161849 54 g-index
92 all docs	92 docs citations	92 times ranked	4161 citing authors

#	Article	IF	Citations
1	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. New England Journal of Medicine, 2014, 371, 1599-1608.	27.0	383
2	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infectious Diseases, The, 2017, 17, 39-49.	9.1	294
3	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. Aids, 2008, 22, 1971-1977.	2.2	195
4	Human Immunodeficiency Virus and the Prevalence of Undiagnosed Tuberculosis in African Gold Miners. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 673-679.	5.6	154
5	Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. Aids, 2007, 21, 1301-1308.	2.2	140
6	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health, 2016, 4, e806-e815.	6.3	138
7	Hepatitis B Virus Infection and Response to Antiretroviral Therapy (ART) in a South African ART Program. Clinical Infectious Diseases, 2008, 47, 1479-1485.	5.8	119
8	Effect of Routine Isoniazid Preventive Therapy on Tuberculosis Incidence Among HIV-Infected Men in South Africa. JAMA - Journal of the American Medical Association, 2005, 293, 2719.	7.4	115
9	Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during Firstâ€Line Antiretroviral Therapy in South Africa. Clinical Infectious Diseases, 2009, 49, 1928-1935.	5.8	107
10	HIV and tuberculosis in prisons in sub-Saharan Africa. Lancet, The, 2016, 388, 1215-1227.	13.7	107
11	The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respiratory Medicine,the, 2022, 10, 603-622.	10.7	99
12	Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. Psychology, Health and Medicine, 2007, 12, 314-320.	2.4	88
13	Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans. Aids, 2003, 17, 2063-2070.	2.2	84
14	Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1558-1566.	3.0	77
15	Does Tuberculosis Increase HIV Load?. Journal of Infectious Diseases, 2004, 190, 1677-1684.	4.0	71
16	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health, 2016, 4, e816-e826.	6.3	69
17	High Tuberculosis Prevalence in a South African Prison: The Need for Routine Tuberculosis Screening. PLoS ONE, 2014, 9, e87262.	2.5	61
18	Comparison of Tenofovir, Zidovudine, or Stavudine as Part of First-Line Antiretroviral Therapy in a Resource-Limited-Setting: A Cohort Study. PLoS ONE, 2013, 8, e64459.	2.5	59

#	Article	IF	Citations
19	Stable Incidence Rates of Tuberculosis (TB) among Human Immunodeficiency Virus (HIV)â€“Negative South African Gold Miners during a Decade of Epidemic HIVâ€Associated TB. Journal of Infectious Diseases, 2003, 188, 1156-1163.	4.0	54
20	HIV Infection Does Not Affect Active Case Finding of Tuberculosis in South African Gold Miners. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1271-1278.	5.6	48
21	Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors. Antimicrobial Agents and Chemotherapy, 2015, 59, 960-971.	3.2	48
22	Four Models of HIV Counseling and Testing: Utilization and Test Results in South Africa. PLoS ONE, 2014, 9, e102267.	2.5	46
23	Autopsy Prevalence of Tuberculosis and Other Potentially Treatable Infections among Adults with Advanced HIV Enrolled in Out-Patient Care in South Africa. PLoS ONE, 2016, 11, e0166158.	2.5	42
24	Cytomegalovirus Viremia as a Risk Factor for Mortality Prior to Antiretroviral Therapy among HIV-Infected Gold Miners in South Africa. PLoS ONE, 2011, 6, e25571.	2.5	40
25	Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 503-510.	3.2	38
26	Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. Lancet HIV,the, 2020, 7, e27-e37.	4.7	32
27	Incidence of HIV-Associated Tuberculosis among Individuals Taking Combination Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e111209.	2.5	31
28	Second-Line Antiretroviral Therapy in a Workplace and Community-Based Treatment Programme in South Africa: Determinants of Virological Outcome. PLoS ONE, 2012, 7, e36997.	2.5	29
29	A clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South Africa. PLoS ONE, 2017, 12, e0181519.	2.5	28
30	Depression and alcohol use disorder at antiretroviral therapy initiation led to disengagement from care in South Africa. PLoS ONE, 2017, 12, e0189820.	2.5	26
31	Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data. PLoS ONE, 2017, 12, e0174097.	2.5	24
32	Universal test-and-treat in Zambian and South African correctional facilities: a multisite prospective cohort study. Lancet HIV,the, 2020, 7, e807-e816.	4.7	20
33	Resistance to Tenofovir-Based Regimens during Treatment Failure of Subtype C HIV-1 in South Africa. Antiviral Therapy, 2013, 18, 915-920.	1.0	19
34	Annual Tuberculosis Preventive Therapy for Persons With HIV Infection. Annals of Internal Medicine, 2021, 174, 1367-1376.	3.9	17
35	Diagnostic Accuracy of Lateral Flow Urine LAM Assay for TB Screening of Adults with Advanced Immunosuppression Attending Routine HIV Care in South Africa. PLoS ONE, 2016, 11, e0156866.	2.5	17
36	HIV testing services in healthcare facilities in South Africa: a missed opportunity. Journal of the International AIDS Society, 2019, 22, e25367.	3.0	16

#	Article	IF	Citations
37	An ecological study to evaluate the association of Bacillus Calmette-Guerin (BCG) vaccination on cases of SARS-CoV2 infection and mortality from COVID-19. PLoS ONE, 2020, 15, e0243707.	2.5	16
38	A novel HIV treatment model using private practitioners in South Africa. Sexually Transmitted Infections, 2012, 88, 136-140.	1.9	15
39	Outcomes of on-site antiretroviral therapy provision in a South African correctional facility. International Journal of STD and AIDS, 2016, 27, 1153-1161.	1.1	14
40	Household HIV Testing Uptake among Contacts of TB Patients in South Africa. PLoS ONE, 2016, 11, e0155688.	2.5	14
41	The association between social capital and HIV treatment outcomes in South Africa. PLoS ONE, 2017, 12, e0184140.	2.5	14
42	Implementing a Large-Scale Systematic Tuberculosis Screening Program in Correctional Facilities in South Africa. Open Forum Infectious Diseases, 2015, 2, ofu121.	0.9	13
43	Protein binding of rifampicin is not saturated when using high-dose rifampicin. Journal of Antimicrobial Chemotherapy, 2019, 74, 986-990.	3.0	13
44	Durable <scp>HIV RNA</scp> resuppression after virologic failure while remaining on a firstâ€line regimen: a cohort study. Tropical Medicine and International Health, 2014, 19, 236-239.	2.3	10
45	The Diagnostic Accuracy of Urine Lipoarabinomannan Test for Tuberculosis Screening in a South African Correctional Facility. PLoS ONE, 2015, 10, e0127956.	2.5	10
46	Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Mycobacterium tuberculosis Specific T Cell Activation and Functional Markers. Frontiers in Immunology, 2020, 11, 572620.	4.8	10
47	Feasibility of implementing same-day antiretroviral therapy initiation during routine care in Ekurhuleni District, South Africa: Retention and viral load suppression. Southern African Journal of HIV Medicine, 2020, 21, 1085.	0.9	10
48	Factors associated with low tuberculosis preventive therapy prescription rates among health care workers in rural South Africa. Global Health Action, 2021, 14, 1979281.	1.9	10
49	Clinic-level factors influencing patient outcomes on antiretroviral therapy in primary health clinics in South Africa. Aids, 2016, 30, 1099-1109.	2.2	9
50	Youth Preferences for HIV Testing in South Africa: Findings from the Youth Action for Health (YA4H) Study Using a Discrete Choice Experiment. AIDS and Behavior, 2021, 25, 182-190.	2.7	9
51	HIV prevalence and the cascade of care in five South African correctional facilities. PLoS ONE, 2020, 15, e0235178.	2.5	8
52	Is HIV Post-test Counselling Aligned with Universal Test and Treat Goals? A Qualitative Analysis of Counselling Session Content and Delivery in South Africa. AIDS and Behavior, 2021, 25, 1583-1596.	2.7	8
53	Description of adverse events among adult men following voluntary medical male circumcision: Findings from a circumcision programme in two provinces of South Africa. PLoS ONE, 2021, 16, e0253960.	2.5	8
54	Understanding factors influencing utilization of HIV prevention and treatment services among patients and providers in a heterogeneous setting: A qualitative study from South Africa. PLOS Global Public Health, 2022, 2, e0000132.	1.6	8

#	Article	IF	Citations
55	Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa. BMJ Global Health, 2018, 3, e000833.	4.7	7
56	Perceptions of Value and Cost of HIV Care Engagement Following Diagnosis in South Africa. AIDS and Behavior, 2018, 22, 3751-3762.	2.7	7
57	Exploring perceptions of low risk behaviour and drivers to test for HIV among South African youth. PLoS ONE, 2021, 16, e0245542.	2.5	7
58	Exploring the promise and reality of ward-based primary healthcare outreach teams conducting TB household contact tracing in three districts of South Africa. PLoS ONE, 2021, 16, e0256033.	2.5	7
59	HIV infection and chronic chest disease as risk factors for bacterial pneumonia. Aids, 2003, 17, 1531-1537.	2.2	6
60	Attitudes to directly observed antiretroviral treatment in a workplace HIV care programme in South Africa. Sexually Transmitted Infections, 2007, 83, 383-386.	1.9	6
61	HIV-related stigma and uptake of antiretroviral treatment among incarcerated individuals living with HIV/AIDS in South African correctional settings: A mixed methods analysis. PLoS ONE, 2021, 16, e0254975.	2.5	6
62	HIV incidence and predictors of inconsistent condom use among adult men enrolled into an HIV vaccine preparedness study, Rustenburg, South Africa. PLoS ONE, 2019, 14, e0214786.	2.5	5
63	Addressing Common Mental Health Disorders Among Incarcerated People Living with HIV: Insights from Implementation Science for Service Integration and Delivery. Current HIV/AIDS Reports, 2020, 17, 438-449.	3.1	5
64	Strengthening the Mentorship and Leadership Capacity of HIV/AIDS and Tuberculosis Researchers in South Africa. American Journal of Tropical Medicine and Hygiene, 2021, , .	1.4	5
65	Household point of care CD4 testing and isoniazid preventive therapy initiation in a household TB contact tracing programme in two districts of South Africa. PLoS ONE, 2018, 13, e0192089.	2.5	5
66	â€œTo speak or not to speakâ€• A qualitative analysis on the attitude and willingness of women to start conversations about voluntary medical male circumcision with their partners in a peri-urban area, South Africa. PLoS ONE, 2019, 14, e0210480.	2.5	4
67	Derivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A cohort study. PLoS Medicine, 2021, 18, e1003739.	8.4	4
68	Enhancing value and lowering costs of care: a qualitative exploration of a randomized linkage to care intervention in South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 481-488.	1.2	3
69	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. PLoS ONE, 2020, 15, e0234937.	2.5	3
70	Effect of Xpert MTB/RIF testing introduction and favorable outcome predictors for tuberculosis treatment among HIV infected adults in rural southern Mozambique. A retrospective cohort study. PLoS ONE, 2020, 15, e0229995.	2.5	3
71	Tuberculosis in prisons: an unintended sentence?. Lancet Public Health, The, 2021, 6, e263-e264.	10.0	3
72	Performance of GeneXpert MTB/RIF for Diagnosing Tuberculosis Among Symptomatic Household Contacts of Index Patients in South Africa. Open Forum Infectious Diseases, 2021, 8, ofab025.	0.9	3

#	Article	IF	Citations
73	Do Incarcerated Populations Serve as a Reservoir for Tuberculosis in South Africa?. American Journal of Tropical Medicine and Hygiene, 2018, 99, 1390-1396.	1.4	3
74	Pregnancy Incidence and Correlates in a Clinical Trial Preparedness Study, North West Province South Africa. PLoS ONE, 2014, 9, e95708.	2.5	2
75	Risk Factors for Hospitalization or Death Among Adults With Advanced HIV at Enrollment for Care in South Africa: A Secondary Analysis of the TB Fast Track Trial. Open Forum Infectious Diseases, 2022, 9, .	0.9	1
76	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa: authors' reply. Aids, 2009, 23, 872-873.	2.2	0
77	Reducing tuberculosis-associated mortality among people with HIV. Aids, 2011, 25, 1556.	2.2	0
78	Title is missing!. , 2020, 15, e0229995.		0
79	Title is missing!. , 2020, 15, e0229995.		0
80	Title is missing!. , 2020, 15, e0229995.		0
81	Title is missing!. , 2020, 15, e0229995.		0
82	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
83	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
84	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
85	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
86	Title is missing!. , 2020, 15, e0243707.		0
87	Title is missing!. , 2020, 15, e0243707.		0
88	Title is missing!. , 2020, 15, e0243707.		0
89	Title is missing!. , 2020, 15, e0243707.		0